Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. Once submitted, the certificate will be automatically generated as a PDF online.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact Nicole Dane via email at ndane@mlieducation.org.
You must be enrolled to complete this activity for credit, however, you are not required to enroll simply to view the presentation.
Target Audience
This CE activity is intended for oncologists, pediatric hematologist-oncologists, nurses, and oncology social workers involved in the care of patients with hematologic malignancies.
Description
This activity will provide an overview of treating pediatric acute leukemia, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Faculty will focus on identifying signs and symptoms, diagnostic tests, treatments, including the importance of clinical trials, and highlight The Leukemia & Lymphoma Society’s PedAL trial, a precision medicine clinical trial for pediatric acute leukemia. Finally, faculty will discuss psychosocial and other survivorship challenges and how to overcome these, including resources for support.
| Educational Objectives — After completing this CE activity, the participant should be better able to: | |
| • | Describe common childhood blood cancers, including AML and ALL |
| • | Identify signs and symptoms of childhood blood cancers and diagnostic tests |
| • | Explain treatments, including the role of clinical trials, and LLS PedAL, a precision medicine clinical trial for pediatric AML |
| • | Describe management of short- and long-term side effects of treatment, follow-up care plans, and communication between the pediatrician/family physician and oncologist |
| • | Describe psychosocial and survivorship challenges and resources to support children and their families |
Accreditation, Support and Credit
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Social Worker Continuing Education
As a Jointly Accredited Organization, Medical Learning Institute, Inc. (MLI) is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. MLI maintains responsibility for the course.
Social workers completing this course receive 1.0 Cultural Competency continuing education credits.
Nursing Continuing Professional Development
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society National Office under Provider Number CEP 5832 to award 1.0 continuing education contact hours through the California Board of Registered Nursing.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
Support Statement
There is no commercial support associated with this CE activity.
To view system requirements please go to https://llsce.org/system-requirements
For questions, grievances, or assistance with special needs (physical, etc.) please contact us at ProfEducation@LLS.org.
Disclosure of Conflicts of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Speaker
| Todd M. Cooper, DO |
| Professor of Pediatrics/University of Washington |
| Evans Family Endowed Chair in Pediatric Cancer |
| Section Chief – Pediatric Oncology |
| Director of the Pediatric Leukemia/Lymphoma Program |
| Co-Director of the High-Risk Leukemia Program |
| Seattle Children’s Hospital |
| Seattle, WA |
Todd M. Cooper, DO, has no relevant financial relationship(s) with ineligible companies to disclose for this educational activity.
Speaker
| Kristina Lopez, LCSW, MSW |
| Information Specialist |
| Information Resource Center |
| The Leukemia & Lymphoma Society |
| Rye Brook, NY |
Kristina Lopez, LCSW, MSW, has a financial interest/relationship or affiliation in the form of:
Advisor/Consultant: AYA ALL Access to Care
Speaker
| Caroline Kornhauser, MPH |
| Senior Manager |
| Professional Education |
| The Leukemia & Lymphoma Society |
| Rye Brook, NY |
Caroline Kornhauser, MPH, has no relevant financial relationship(s) with ineligible companies to disclose for this educational activity.
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and The Leukemia & Lymphoma Society, the joint provider do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Planner
| Lauren Berger, MPH |
| The Leukemia & Lymphoma Society |
| Rye Brook, NY |
Lauren Berger, MPH, has a financial interest/relationship or affiliation in the form of:
Stock Ownership with Bristol Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc., Organon & Co., Pfizer Inc., and Viatris Inc.
All of the relevant financial relationships of individuals for this activity have been mitigated.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities
| Estimated time to complete activity: 1.0 hours |
| Date of initial release: May 27, 2022 |
| Expiration date: May 27, 2023 |
 |
|
Todd M. Cooper, DO, strongest interests include national and international pre-clinical and clinical trial development testing novel approaches to therapy for children with relapsed hematologic malignancies. To that end, I have developed and provided leadership for Phase I/Developmental Therapeutics programs at the University of Alabama at Birmingham and Children’s Healthcare of Atlanta/Emory University. I have been fortunate to lead Phase I studies of new agents for relapsed acute leukemia in a variety of national consortia. More precisely, I have been principal investigator of Phase I and Phase II studies in the Therapeutic Advances for Childhood Leukemia (TACL) Consortium, Pediatric Oncology Experimental Therapeutics Investigator Consortium (POETIC), and the Children’s Oncology Group (COG) Consortium. Each of these trials has resulted in publication. I currently serve as the chair of the COG Acute Myeloid Leukemia (AML) New Agents Committee and actively collaborate internationally to help maintain a cohesive strategy for the treatment of children with acute leukemia. More recently, I am currently leading the COG Phase III study for newly diagnosed children with AML which is actively accruing with an accrual of 1400 patients expected. Finally, I have been appointed as Principal Investigator for a Leukemia/Lymphoma Society-funded master trial for relapsed pediatric AML. This international trial will match children with novel targeted therapies based on centralized next generation genomic sequencing. With the support of LLS, I frequently engage with industry partners, the FDA and EMA in discussing individual new drugs, trial design, and standards for toxicity and response assessment for children with relapsed acute leukemia. I am intimately involved in the selection of new agents, designing and leading clinical trials, all with the goal of bringing positive change to the therapy of children diagnosed with AML both nationally and internationally.
 |
|
Kristina Lopez, , LCSW, MSW is a bilingual/bicultural Information Specialist with the Leukemia and Lymphoma Society’s Information Resource Center (IRC). She is part of a team of highly trained oncology professionals who help to support people impacted by blood cancer through education and resources. Kristina is a Licensed Clinical Social Worker, a certified supervisor for clinical social work interns in the state of Florida, and has been involved in education in various forums including the NASW, CancerCon, and Noticias Ya. Prior to joining the IRC team, Kristina worked at Nemours Children’s Hospital in Orlando, Florida for almost 8 years – 4 of those years focused on pediatric Hematology/Oncology. She also worked as a counselor for primarily Medicaid clients. Kristina attended the University of Central Florida (UCF) and graduated in 2010 with her bachelor’s degree in Social Work and minor in Nonprofit Management. She obtained her master’s degree from her alma mater in 2011. Kristina has a passion for serving at risk populations including the Latinx and LGBTQ+ communities as well as has special interests in DEI and access to care.
Resources for You
- FREE CME and CE courses for healthcare professionals: www.LLS.org/CE
- Staying Connected: Facilitating the Learning Experience During and After Cancer Treatment, online CE program for school nurses, social workers, teachers and other school personnel. Focuses on medical, education & psychosocial support for children & AYAs treated for any type of cancer – www.LLS.org/StayingConnected
- Treating Blood Cancers Podcast series for healthcare professionals: www.LLS.org/HCPpodcast. Experts discuss the latest developments in blood cancers, new and emerging treatment options, side-effect management, survivorship issues, and more. Pediatric and AYA topics include:
- Wearing Two Hats: Supporting the Childhood Cancer Patient as Nurse & Parent
- Long-Term & Late Effects of Childhood Cancer
- Childhood Blood Cancers
- Pediatric Survivorship
- Facilitating the Learning Experience of Children and AYAs During and After Cancer Treatment
- LLS Online Community: HCP, Patient/Survivor & Caregiver account types: www.LLS.org/community
- Safe and secure site dedicated to research and has been created to support those living with blood cancer, their closest family members and healthcare professionals.
- Information Resource Specialists: Nurses, social workers, and health educators who assist through treatment, financial, and social challenges. They offer up-to-date disease and treatment information – www.LLS.org/IRC
- Clinical Trial Nurse Navigators: Registered Nurses with expertise in blood cancers personally assist through the clinical trial process with patients, caregivers or HCPs – www.LLS.org/navigationOr, refer your patient directly – www.LLS.org/CTSCreferralOur support team provides an additional resource to your HCP team.
- Phone: (800) 955-4572, M-F, 9 am to 9 pm ET
- Email: infocenter@LLS.org
Live chat: www.LLS.org/InformationSpecialists
Resources for Patients
- Childhood blood cancer resources: www.LLS.org/Childhoodcancer
- Follow-up care for childhood blood cancer survivorship: www.LLS.org/ChildhoodFollowUp
- Telephone and web education programs: www.LLS.org/Programs and www.LLS.org/Educationvideos for patients and caregivers
- Free booklets and fact sheets on disease, treatment and survivorship: www.LLS.org/Booklets
- Examples include: Living and Learning with Cancer, Long-term and Late Effects of Leukemia & Lymphoma Facts, Young Adults and Cancer, Young Adult Journal, Fertility and Cancer, Pictures of My Journey
- Support resources: www.LLS.org/Support
- Financial assistance
- Co-Pay
- Travel Assistance
- Referral to medication access programs
- LLS regions
- LLS Community (social media platform)
- Online chats
- Patti Robinson Kaufman First Connection Program (peer-to-peer)
- One-On-One Nutrition Consultations (PearlPoint)
- Financial assistance
- The LLS Children’s Initiative: Cures & Care for Children – LLS’ multi-year endeavor to attack pediatric blood cancer – research grants, education and support for children and their families, new policy and advocacy efforts – www.LLS.org/childrens-initiative
- PedAL: Global precision medicine master clinical trial that will test multiple targeted therapies simultaneously at up to 200 clinical sites worldwide to treat children with relapsed acute leukemia, working in collaboration with NCI & COG – www.LLS.org/lls-childrens-initiative-pedal
If you have any questions, please contact us at ProfEducation@LLS.org or call our Information Resource staff at 800-955-4572.